Our innovative pipeline of novel targets
We aim to develop first-in-class therapeutics that addresses critical unmet medical needs. Our R&D is currently focused on colorectal cancer, a high-impact disease with limited treatment options. Driven by a patient-centric approach, we are advancing a dynamic pipeline of innovative targets and modalities, including both small molecules and biologics.
Indivumed Pipeline of small molecules and biologics
Do you want to learn more?
Get in touch if you are interested in details of our current and future pipeline, ongoing development programs, or additional indications. We can address CRC, NSCLC, and other solid tumors. Looking forward to discuss a potential collaboration.
Our Pipeline What makes our assets stand out?
Our targets are the result of a patient-centric approach that is truly unique from the very first step. Starting with nonischemic, highly standardized tumor samples from patients all over the world, we create proprietary multi-omics datasets. In our holistic target identification and validation process, we utilize this data as well as the source samples to enhance the probability of successful therapeutic development.
)
“Our R&D approach brings novel insights through our unique starting point. Carefully collected and curated patient samples are excellent representations of the characteristic features of the disease, making the difference in target discovery and lead generation toward innovative and successful therapeutics.”